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The physiological significance of parathyroid hor-
mone in the regulation of bone resorption and serum
calcium was established by the work of Collip [1] and
others in the 1920's. Early investigators also recog-
nized that the kidney was important in parathyroid
hormone action. Greenwald and Gross discovered
that parathyroidectomy caused a rapid fall in the rate
of excretion of phosphate into the urine, and that
injection of parathyroid extract caused urine phos-
phate excretion to rise [2]. The effect on phosphate
excretion was so rapid as to lead some to believe that
regulation of calcium was mediated through the hor-
mone's phosphaturic influence on the kidney [3].
Physiologists later proved that parathyroid hormone
acts directly on bone as well as on kidney. The kidney,
moreover, has been established as an important organ
mediator for regulation of calcium in the extracellular
fluid. The role of the kidney as an effector of para-
thyroid action, however, is due to its influence on cal-
cium, not phosphate excretion.
The subsequent discovery [4] of calcitonin, another
hormone involved in regulating calcium metabolism,
led to the finding that it too influences renal physio-
logy. It causes an increase in urinary excretion of
sodium, phosphate and calcium. Moreover, specific
hormone receptors for calcitonin in the nephron have
been identified, Nevertheless, it is still unclear whether
these renal effects of calcitonin are important in its
physiological control of calcium. In this paper we
discuss the physiological actions' of parathyroid
hormone and calcitonin on the kidney.
1 This treatise is necessarily limited in scope. A fair presenta-
tion of the extensive literature in this area would require much
more space than allocated. We hope we have provided at least
a useful outline and introduction to the literature and apologize
for omitting citation of many important pieces of research.
© 1974, by the International Society of Nephrology.
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Hormonal control of solute transport in the kidney
Phosphate. No one renal influence of the parathyroid
hormone has been studied more extensively than the
phosphaturic effect. Greenwald and Gross were the
discoverers of this effect, and Albright and Reifenstein,
the major exponents of its physiological significance.
At one time their school believed that parathyroid
hormone controlled calcium metabolism through the
renal phosphaturic effect [3]. This view is no longer
considered but there are still controversies as to
whether the hormone affects phosphate directly or
indirectly and whether this effect is brought about by
decreased tubular reabsorption or increased tubular
secretion. Moreover, whatever the tubular function
affected, which part of the tubule expresses the physio-
logical response?
There is no question that much of the confusion in
early experiments was generated through spurious
results caused by the gross impurities in the crude
extracts used. Collip's extract [1] and the generally
available commercial version of it represent only 1 %
parathyroid hormone; 99% of the protein content
represents contaminants. It is likely that the effects on
blood pressure and glomerular filtration rate (GFR)
found in some experiments can be attributed to con-
taminating proteins and peptides. Development of
purified parathyroid preparations allowed definitive
conclusions that the phosphaturic effect must be
attributable to a tubular influence of the hormone
without changes in GFR. Intravenous infusion of
parathyroid hormone causes a rapid and dramatic
increase in phosphate excretion [5] and this can be
reproduced by injection directly into a single renal
artery [6]. These experiments were among the first to
prove the direct action of parathyroid hormone on the
kidney.
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1) Physiological mechanisms within the kidney. The
direct effect of the hormone on the kidney in producing
phosphaturia is now accepted; on the other hand,
there is still a question as to the exact tubular mechan-
ism involved. Parathyroid hormone injected into the
renal portal system of the chicken produces phospha-
tuna [7], suggesting the possibility that the hormone
influences secretion. Moreover, occasional experiments
have shown hormone-induced increments in phosphate
excretion that exceeded the amount of phosphate
filtered [8]. However, few will accept without further
proof that parathyroid hormone causes tubular secre-
tion of phosphate. Most generally accepted is the
postulate that parathyroid hormone inhibits tubular
reabsorption of phosphate from the glomerular filtrate.
There are several recent studies of parathyroid
hormone influence on tubular phosphate determined
by the micropuncture technique [9—li]. Findings of
these several experiments are considered to support
primary effect of parathyroid hormone on inhibition
of proximal phosphate reabsorption. Still more recent
information [12] suggests that the hormone can influ-
ence phosphate reabsorption not only in the proximal
tubule but in the distal tubule as well. Finally, it is
important to consider that the transport function
influenced by parathyroid hormone in the kidney is
not represented by an effect on phosphate transport
per se. The transport process specifically effected by
parathyroid hormone indeed may be sodium trans-
port (see following).
2) Extracellular volume expansion. It has been
known for some time that expansion of the extracellu-
lar fluid volume causes an increase in sodium and phos-
phate excretion. It has been proposed that this natri-
uretic effect is regulated physiologically by a hormone
as yet undiscovered (see discussion by De Wardener
[13]. This elusive humoral agent has never been
identified, nor have its physiological functions been
defined. On the other hand, recent evidence suggests
that some, if not most, of the phosphaturic response
to extracellular volume expansion is attributable to
increased rates of parathyroid hormone secretion.
Findings of several studies [14—16] indicate that para-
thyroidectomy abolishes the phosphaturic response to
volume expansion. Moreover, another study [17]
shows that volume expansion produced by albumin
infusions causes phosphaturia dependent upon intact
parathyroid glands and associated with increased
secretion of parathyroid hormone.
3) Calcitonin. Early studies [18] showed that calci-
tonin can influence phosphate excretion; this subject
has been discussed in a recent review [19]. The physio-
logical significance of this effect of calcitonin has been
doubted because the effects are small and elicited only
under certain circumstances. Moreover, there have
been challenges to the proposal that the phosphaturic
action of calcitonin is produced by a direct effect on
the kidney itself. On the other hand, it is now clear
that calcitonin can interact directly with specific renal
receptors within the kidney (see Hormone receptors in
the kidney and generation of cyclic 3, 51-AMP).
Sodium transport. Agus [12] has studied the influ-
ence of parathyroid hormone in the proximal tubule
through application of the micropuncture technique.
He found with micropuncture studies that parathyroid
hormone causes inhibition of sodium reabsorption in
the proximal tubule, and proposed that this accounts
for the phosphaturic effect of the hormone, Phosphate
might simply follow as the counter ion. When the
proximally rejected sodium phosphate reaches the
distal tubule, most of the sodium is reabsorbed, but
the distal tubular cell is relatively impermeable to
phosphate which (accompanied by potassium and
hydrogen) passes out into the urine. It is of interest
that Gill and Casper [20] found similar effects of
catecholamines on the kidney. In hypophysectomized
dogs, they found evidence that catecholamines inhibit
proximal sodium reabsorption with the net result of
an increase in free water clearance. Thus, these two
hormones, parathyroid hormone and fl-adrenergic
catecholamines, seem to influence sodium transport
in the proximal tubule but do not necessarily produce
marked natriuresis. Calcitonin, on the other hand, at
least when given in large doses, increases the rate of
sodium clearance. The latter effect of calcitonin has
been observed in man as well as dogs [19]. It is tempt-
ing to propose that, although both parathyroid hor-
mone and calcitonin influence sodium transport in
the kidney, the ultimate expression of these effects
are distinct because the sites of action within the
renal tubule for these two hormones are distinct.
There is suggestive evidence that the site for para-
thyroid hormone action in the kidney is located more
proximally (in the cortex) within the nephron than is
the site for calcitonin. The area of the kidney found
most sensitive to calcitonin was the outer medullary
zone [21]. Thus, it is possible that influences on sodium
reabsorption in the early proximal tubule are reflected
by increased water clearance, whereas the influence
of calcitonin lower in the nephron is reflected in
natriuresis.
Calcium transport in the kidney. The evidence that
parathyroid hormone regulates calcium clearance in
the kidney is now overwhelming. In general, the
hormone causes a decrease in calcium clearance at any
given concentration of calcium in the extracellular
fluids [22—25]. Parathyroidectomy causes an acute
increase in calcium excretion, an observation made
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originally by Talmage and Kraintz [24] with rats. In
the golden hamster, the increase in urinary calcium
seems to account completely for the loss of calcium
from the extracellular fluids in the first hours after
parathyroidectomy [26]. Nordin and Peacock [25] had
presented evidence that the regulation of calcium
clearance by parathyroid hormone is important in
controlling blood calcium in man. The exact mechan-
ism for this effect of parathyroid hormone, however, is
not known.
Calcium clearance is closely linked [27—29] to
sodium clearance in the kidney, and it is conceivable
that calcium and sodium share a common transport
mechanism at some locus in the renal tubule. The
effect of parathyroid hormone on calcium clearance,
however, appears to occur distally [23] in contrast to
the proximal locus assigned for the hormone effect on
phosphate. On the other hand, calcium clearance is a
linear function of sodium clearance in normal subjects
and increases with sodium intake. Mannitol or saline
diuresis causes an increase of calcium clearance paral-
leling a rise in sodium clearance, and calcium may be
reabsorbed at the same portions of the nephron as is
sodium. Moreover, there is a parallel increase in calci-
um and sodium concentration in the ioop of Henle
and throughout the nephron [29]. It is also of interest
that the hypercalcemic effects of thiazide diuretics are
dependent on the presence of the parathyroid glands
[30]. It is possible, then, that changes in calcium
clearance influenced by parathyroid hormone might
be brought about secondarily through a primary
influence of the hormone on sodium transport in the
renal tubule. Parathyroid hormone acts through the
intermediation of cyclic 3', 5'-adenosine monophos-
phate (AMP) [31], and it is known that this nucleotide
regulates sodium transport in at least three tissues.
Cyclic AMP generated in the toad bladder in response
to vasopressin [32] and in the frog skin [33] or avian
erythrocyte [34, 35] in response to -adrenergic
agonists causes an immediate increase in sodium trans-
port. Since both parathyroid hormone and calcitonin
act on the kidney through the intermediation of cyclic
AMP, it is conceivable that regulation of sodium
transport in the renal tubule is the function affected
directly by action of these hormones on the kidney.
Further, of possible significance in this regard is the
observation that ouabain increases both sodium and
calcium clearance, probably by inhibiting reabsorption
in the ascending limb of the ioop of Henle and distal
tubule (see discussion by Walser [29]). It should be
emphasized, however, that enhanced clearance caused
by ouabain does not prove inhibition of transport;
under certain circumstances, ouabain potentiated
3',5'-AMP-mediated sodium and potassium transport
in avian erythrocytes [35]. In any event, these several
observations suggest the possibility that changes in
calcium transport in the nephron may be due to a
primary effect on sodium fluxes.
Conversely, experiments with renal cells in vitro
suggest the possibility that calcitonin or parathyroid
hormone can regulate cellular transport of calcium
directly, not necessarily secondarily through regulation
of sodium transport (see review by Borle [36]). It has
been proposed that mitochondria within cells act as
an intracellular reservoir of calcium and that intra-
cellular cyclic AMP can regulate the rate of release of
calcium from mitochondria [36]. Whether mito-
chondria have any role in mediating effects of para-
thyroid hormone, calcitonin or cyclic AMP under
normal physiological circumstances remains to be
established. Studies in this area are complicated by
uncertainty in attempting to correlate changes ob-
served with isolated mitochondria with those occurr-
ing physiologically in the intact organism.
Changes in bicarbonate excretion. Excessive para-
thyroid function is associated with decreased capacity
for reabsorption of bicarbonate in the proximal
tubule [37—40], and injection of parathyroid extract
causes an increase in excretion of bicarbonate [41].
Heliman, Au and Bartter [41] found that an increase
in bicarbonate excretion was one of the earliest renal
responses to administration of parathyroid extracts
in dogs. Moreover, Muldowney et al [39] reported
that the acidosis of uremia is attributable, at least in
part, to excessive secretion of parathyroid hormone
(secondary hyperparathyroidism). They, as well as
Siddiqui and Wilson [38] found that some patients
with primary hyperparathyroidism develop a type of
proximal renal tubular acidosis and this is corrected
following parathyroidectomy. It is also known that
the normal rate of secretion of parathyroid hormone
aggravates the proximal tubular acidosis of hereditary
fructose intolerance [42]. It appears, then, that para-
thyroid hormone may have a direct effect, again possi-
bly mediated by cyclic 3',5'-AMP, on decreasing the
ability of the proximal tubule to reabsorb bicarbonate.
It is unclear whether this reflects a direct effect on
bicarbonate or whether it too may be due to effects on
sodium transport.
Hexose and amino acid transport. Changes in blood
glucose concentration and development of glycosuria
are among the earliest observations on the physio-
logical effects of parathyroidectomy or administration
of parathyroid extracts [43—54]. The renal threshold
for glucose seemed to be reduced in that glycosuria
was reported following parathyroidectomy, and in
the absence of the parathyroid glands, glycosuria
occurred after subcutaneous injections of glucose.
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One observer [44] reported marked hypoglycemia in
tetanic dogs but this result apparently has never been
confirmed by others. Another group reported that
parathyroid extracts were hypoglycemic and claimed
this use effective in treating seven patients with dia-
betes mellitus. They also reported that chronic ad-
ministration of parathyroid extract led to pancreatic
islet cell hyperplasia.
Few of these early experiments with crude extracts
were conclusive, but there was a definite suggestion
that parathyroid hormone might effect renal glucose
transport. Clarification of some of these findings
followed the studies of Halver [55—58] and Transbol
and Halver [59]. They determined maximal tubular
reabsorption of glucose (TmG) in various disorders of
calcium metabolism and found TmG high in most
cases of hyperparathyroidism and low in hypopara-
thyroidism. Parathyroidectomy caused a fall in TmG
and parathyroid extract raised the low values found in
the hypoparathyroid subjects. Further studies [58]
showed the TmG to be increased in one case of
pseudohypoparathyroidism.
In sarcoidosis with hypercalcemia (a state associated
with low rates of parathyroid secretion), the TmG was
usually low, but in two subjects it was elevated and at
subsequent surgery both showed abnormal parathy-
roid histologic findings [59]; one patient had a para-
thyroid adenoma, and the other, four-gland hyper-
plasia.
These results of Halver were not confirmed by
Aurell et al [60] but have been confirmed by Heath
and Knapp [61—62]. The latter found that TmG is
high in 50 to 60% of hyperparathyroid subjects;
there was a larger overlap with normal subjects than
found by Halver. The degree of overlap and the
difficulties in accurate determination of TmG make
it unlikely that this test will ever be important in
diagnosis of hyperparathyroidism.
In hereditary fructose intolerance, the administra-
tion of fructose causes a complex disturbance of
proximal renal tubular dysfunction including impaired
reabsorption of phosphate, amino acid, glucose, uric
acid and bicarbonate. Morris, McSherry and Sebastian
[42] have shown that these induced tubular dysfunc-
tions depend on circulating parathyroid hormone.
In the hypoparathyroid state, the abnormal response
to fructose develops only when parathyroid hormone
is given. The metabolic defect in hereditary fructose
intolerance is lack of the enzyme aldolase B; as a
result, fructose-i-phosphate accumulates in tissues.
It therefore seems possible that parathyroid hormone
regulates the rate at which fructose is taken up into
the renal cortical cell and metabolized to fructose-i-
phosphate. The "protective role" of hypoparathyroid-
ism in this state might thus be explained by reduced
renal reabsorption of sugars.
Recent in vitro studies on the effects of cyclic nucleo-
tides on hexose transport offer further indirect support
for the idea that parathyroid hormone modifies this
transport system. The action of parathyroid hormone
is mediated through production of cyclic AMP. Rea
and Segal [63] have found that cyclic AMP and di-
butyryl cyclic AMP (DCAMP) increase the uptake
of alpha-methyl-D-glucose by slices of rat, rabbit, dog
and human renal cortical tissue. This effect was
dependent on preincubation for at least 90 mm with
the nucleotide and the continuing presence of the
nucleotide during exposure to sugar. No effects were
noted on the transport of D-galactose which is rapidly
metabolized; nor with 0.3-0-methyl-D-glucose, 2-
deoxy-D-glucose and xylose, sugars which do not
share the glucose reabsorptive mechanism. Kinetic
analysis of the data indicated that the changes were
a result of an increase in the maximum velocity of the
uptake mechanism. These results in vitro complement
the studies in human subjects and taken together
strongly suggest that parathyroid hormone increases
the reabsorption of hexoses in the proximal renal
tubule. It is of interest that DCAMP is thought
to increase glucose transport in rat adipose tissue
[64].
Possible explanations of parathyroid hormone
action on hexose transport. (a) Relationship between
reciprocal changes in phosphate transport. Phosphate
and glucose are thought to share in part a common
reabsorptive mechanism so that glucose reabsorption
depresses phosphate reabsorption. The reabsorptive
routes are not identical, however, as phloridzin, which
effectively blocks glucose reabsorption, causes an
increase in phosphate reabsorption [65]. Moreover,
changes in TmG can occur without reduction in
phosphate reabsorption. For example, Halver [58]
reported a high TmG in pseudohypoparathyroidism,
and Heath and Knapp [61, 62] found high TmG
results in nephrotic syndrome with normal phosphate
reabsorption.
(b) Relationship to sodium reabsorption. Active tran-
sport of glucose is a sodium-dependent process and
changes in sodium transport can cause corresponding
changes in glucose transport. The action of parathyroid
hormone in the proximal tubule, however, produces
divergent effects on the two processes, increased glu-
cose reabsorption and decreased sodium reabsorption.
Thus, it is not readily apparent how parathyroid-
mediated sodium transport in the kidney could explain
effects of the hormone on renal hexose transport.
Actions of parathyroid hormone on amino acid
transport. Aminoaciduria is a well-recognized but
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infrequently documented feature of hyperparathyroid-
ism. In 1968 Hockaday, Wade and Keynes [661
reported a case of hyperparathyroidism with increased
urinary excretion of glycine, beta-aminoisobutyric
acid and beta-alanine. The glycinuria was due to
reduced tubular reabsorption whereas excretion of the
other two amino acids was due to an increased filtered
load. These changes disappeared after parathyroid-
ectomy and the authors commented that similar
changes in amino acid excretion had commonly been
observed by them in other cases of hyperparathyroid-
ism. Muldowney, Freaney and McGeeney [67] noted
a more generalized aminoaciduria in two of eight
patients with hyperparathyroidism. Both patients
showed extensive bony changes, and the aminoaciduria
disappeared after parathyroidectomy. Similar urinary
changes were induced in two normal subjects and in
one hypoparathyroid patient following an infusion of
parathyroid extract.
In osteomalacia, aminoaciduria is a well-recognized
finding although the explanation has been unclear.
The studies of Muldowney et al show that aminoacid-
uria, at least in some forms of osteomalacia, is due to
secondary hyperparathyroidism. They found that in
osteomalacia (most in their series caused by celiac
disease or gastrectomy), aminoaciduria could readily
be corrected by calcium infusion. In a case of osteo-
malacia with associated hypoparathyroidism, amino-
aciduria was absent but developed after administration
of parathyroid extract. The amino acids found in the
urine were predominantly glycine, alanine, lysine,
tyrosine and histidine; these are the amino acids
commonly excreted in disorders of renal tubular
reabsorption.
(4) Amino acid transport in vitro. Weiss, Morgan
and Phang [68] and Phang, Downing and Weiss [69]
reported that cyclic AMP or DCAMP stimulates
active uptake of several amino acids, including amino-
isobutyric acid (AIB), glycine, L-leucine, L-lysine,
L-arginine and L-proline, by renal cortical slices of rat.
Administration of parathyroid hormone also stimu-
lated the uptake of AIB but antidiuretic hormone and
insulin had no effect. The nucleotides or parathyroid
hormone were effective only after incubation for 90
mm or more, and studies with inhibitors suggest these
effects may require the synthesis of a protein inter-
mediate. Ouabain or sodium lack also blocked
effectively nucleotide-induced uptake indicating that
sodium-dependent mechanisms were involved. Studies
from the same group have shown similar effects of
nucleotides and parathyroid hormone on the uptake
of amino acids by fetal rat calvaria [69, 701.
The in vitro studies showing increased amino acid
transport seem contradictory to observations of
decreased transport in vivo. An explanation may lie
in the studies of Rosenbusch and Nicholls [71] on
the effects of parathyroid hormone on AIB uptake of
isolated bone cells of rats. They found that following
the administration of a single large dose of hormone,
the initial uptake of AIB was increased at 8 to 12 hr
but was followed at 48 to 72 hr by a decrease uptake.
Chronic administration of parathyroid hormone
caused a 50% reduction in AIB transport. The
biphasic responses in amino acid uptake mirrored
the changes induced in collagen biosynthesis.
If similar biphasic responses occur in the kidney,
this would explain the differences noted, as the studies
of Weiss were performed within hours of exposure to
parathyroid hormone.
Hormone receptors in the kidney and generation of
cyclic 3', 5'-AMP
Classical physiological experiments proving that
parathyroid hormone acts directly on the kidney as
well as on bone show clearly that the nephron must
contain receptors specific for parathyroid hormone.
It is now apparent that the actions of the hormone on
the kidney depend upon the following sequence of
events: interaction of the hormone with specific recep-
tor loci within the nephron; activation of adenylate
cyclase as a result of interaction with receptors;
generation of intracellular cyclic 3', 5'AMP; presumed
activation of protein kinase within the renal cell; and,
as a consequence, activation of systems mediating ion
transport. There is considerable evidence supporting
this overall sequence for hormone action in the kidney
(indeed, a parallel scheme has been developed for
many hormone-receptor systems) and certain steps of
the sequence are supported by hard experimental data.
Moreover, studies in intact animals or man lend
particular physiological relevance to the in vitro
findings. For example, parathyroid hormone in vivo
produces a prompt increase in urinary excretion of
cyclic 3',5'-AMP [72—74}. This effect reflects cyclic
nucleotide elaborated from renal cells responding
directly to the hormone in vivo. Other experiments
show that injection of theophylline or dibutyryl cyclic
3',5'-AMP [75—77] in vivo can mimic the phosphaturic
effect of parathyroid hormone in vivo (see also
Urinary excretion of cyclic 3',5'-AMP). The effect of
the hormone on urinary cyclic AMP can be regarded
as the physiological consequence of direct activation
of adenylate cyclase in the kidney by parathyroid
hormone.
Pharmacological experiments. Parathyroid hormone
perfused in vivo causes phosphaturia [2—8, 72, 73],
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in dogs, rats or man. The effect of DCAMP is qualita-
tively very similar to that of administration of large
doses of parathyroid hormone [75—78]. Theophylline
potentiates the effect of DCAMP but not of para-
thyroid hormone.
The findings of Agus et al [9] suggest that DCAMP
mimics also the effect of parathyroid hormone on
inhibition of sodium reabsorption in the proximal
tubule. 5'-AMP used as a control caused no effect.
These observations are similar to those of Gill and
Casper, who showed that administration of DCAMP
inhibits proximal sodium reabsorption in hypo-
physectomized dogs [78]. The phosphaturia caused by
the nucleotide analogue is qualitatively similar to
that of parathyroid hormone and presumably is
explained by a similar intrarenal mechanism: proxi-
mal inhibition of sodium resorption. The sodium is
reabsorbed distally but phosphate rejected proximally
as the accompanying anion is excreted into the urine
since the distal tubule is relatively impermeable to
phosphate.
There is only suggestive evidence that the effect of
parathyroid hormone on calcium clearance by the
kidney also involves the intermediation of cyclic
3',5'-AMP. Early in the course of the perfusion experi-
ments by Rasmussen, Pechet and Fast [75], there was
an initial decrease in calcium excretion analogous to
that produced by acute effects of parathyroid hormone
administration.
Renal tissue in vitro. Isolated renal tubules also
show an increase in cyclic AMP concentration when
incubated in vitro with parathyroid hormone [79].
Accumulation of cyclic 3',5'-AMP within renal tubules
in response to administration of parathyroid hormone
in vitro leads to an increase in the rate of gluconeo-
genesis from lactate [80]. This seems to be analogous
to the increase in gluconeogenesis in perfused liver
preparations in response to glucagon administration
[81]. Gluconeogenesis in the renal tubule also was
produced by administration of DCAMP. The exact
physiological significance of this gluconeogenic res-
ponse is not clear. It might reflect a function mediated
by an intermediate common to cyclic 3',5'-AMP-
regulated ion transport. It is of interest that cyclic
3',5'-AMP seems to regulate both ion transport and
gluconeogenesis in the liver [81].
Administration of parathyroid hormone also causes
an increase in cyclic AMP concentration in slices [82]
prepared from the renal cortex. Slices from the renal
medulla respond to vasopressin but not to parathyroid
hormone [82].
Cyclic 3',5'-AMP content in kidney tissue. Ad-
ministration of parathyroid hormone causes a prompt
rise in concentration of cyclic 3',5'-AMP in kidney
in vivo or in vitro. Within two minutes after i.v.
injection of parathyroid hormone in rats, the con-
centration of cyclic 3',S'-AMP doubles in the kidney
[83]. This effect is independent of the vitamin D
status of the animal. Increased concentration of cyclic
AMP in the renal cortex is reflected also in the
urinary excretion of the cyclic nucleotide. Injection
of the hormone into parathyroidectomized rats causes
a marked and rapid increase in urinary excretion of
cyclic 3',5'-AMP. Increased excretion of the cyclic
nucleotide precedes the phosphaturic response and is
the earliest response to the hormone detectable in
vivo. Conversely, inhibiting secretion of parathyroid
hormone by increasing blood calcium or removing the
parathyroid glands causes a decrease in excretion of
urinary cyclic AMP [72].
Receptors for parathyroid hormone in kidney. Spec-
ific receptors for polypeptide and amine hormones
have now been identified in a number of systems
[84]. In most instances these studies have depended
upon preparation of high specific activity radio-
iodinated hormones and study of binding of the
labelled hormones to plasma membrane fractions.
Physiological specificity can be assumed if binding of
the labelled hormone to receptor sites shows affinities
comparable for biological activity (for example,
adenylate cyclase activation) in vitro, if only biologi-
cally relevant hormone analogues are effective in
competing for binding, and if the system is specific
for the hormone in question without significant inter-
action from other unrelated proteins, peptides or
hormones.
Recent reports suggest that specific receptors for
parathyroid hormone can be identified in the renal
cortex. Sutcliffe et al [85] reported that '251-parathy-
roid hormone prepared in accordance with the lacto-
peroxidase method binds specifically to membranes
from bovine kidneys. They found no inhibition of
binding with vasopressin, growth hormone, glucagon or
adrenocorticotropic hormone (ACTH), but significant
displacement with insulin. They did not show a com-
plete dose-response curve, but the information given
suggested a (Km) of approximately 0.5 to 1 x 1O M.
DiBella et al [86] recently reported binding of electro-
lytically iodinated (low specific activity) parathyroid
hormone also using bovine renal cortex. They found
Km considerably higher, approximately 5 x 10 M,
and reported no interference with insulin. They appar-
ently did not test ACTH. We [87] similarly have found
apparent specific binding of iodinated parathyroid
hormone (lactoperoxidase or modified chloramine-T
method; specific activities, 75 to 100 Ci/g) also in
the bovine renal cortex. Apparent binding affinities
were in the same ranges (there is some variation in
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apparent affinity from experiment to experiment);
10-v M caused approximately 50% displacement of
iodinated parathyroid hormone from the apparent
receptor. There was, however, significant inhibition of
binding by ACTH; 10 zg/m1 (2 x 10-6 M) ACTH was
as effective as 10-v M (1 g/ml) parathyroid hormone.
Calcitonin or bovine growth hormone also caused
slight inhibition of binding of parathyroid hormone.
The effect of ACTH administration is of considerable
concern because there is no apparent effect of ACTH
at similar concentrations on the biological activity of
parathyroid hormone in vitro. If the binding site were
specific and strictly relatable to biological activity, then
the interaction at this site (detected by inhibition of
binding of labelled parathyroid hormone) would be
expected to inhibit biological activity in vitro. Such
inhibition is not observed.
Adenylate cyclase. Interaction of many polypeptide
or amine hormones with specific hormone recep-
tors leads to activation of the membrane-bound en-
zyme adenylate cyclase. Enzyme activity is assayed
by determining conversion of radioactive adenosine
triphosphate (ATP) to radioactive cyclic 3',5'-AMP
[88]. The enzyme can be obtained as a crude particu-
late fraction by homogenizing tissue and collecting
membrane fragments sedimenting in low gravitational
fields. The plasma membrane of renal cortical cells
contains adenylate cyclase specifically stimulated by
parathyroid hormone. Addition of parathyroid hor-
mone to such preparations causes an increase in adeny-
late cyclase activity. The Km for parathyroid hormone
in activating the enzyme is in the range of 4 x 10 M
[89—90].
Localization of receptors in kidney. Although
several hormones can interact with receptors in the
kidney and influence, thereby, renal metabolic func-
tions, it is apparent that hormone receptors are distri-
buted in distinct locations within the nephron. Dis-
section of the rat kidney shows that parathyroid
hormone stimulates adenylate cyclase predominantly
in the cortex, whereas vasopressin stimulates the
enzyme in the medulla [82, 91]. These findings fit the
physiological concept that vasopressin acts predomin-
antly on the collecting tubules of the kidney and that
parathyroid hormone influences sodium (and phos-
phate) transport across the proximal tubule. Further
studies utilizing the isolated renal tubule preparation
have shown that preparations from the renal cortex
contain the parathyroid hormone receptor, whereas
tubular components of the medulla respond to vaso-
pressin [79]. These several studies lead to the conclu-
sion that renal receptors for parathyroid hormone and
vasopressin are localized to tubules of the renal
cortex and renal medulla, respectively. These studies
do not distinguish between the proximal vs. distal
tubular sites in the cortex for parathyroid hormone.
However, micropuncture studies [9] suggest that the
effect of parathyroid hormone on phosphate in the
kidney occurs at a proximal tubular locus.
Calcitonin receptors in the kidney. Although the
physiological significance of calcitonin effects on the
kidney is still ill-defined, it is clear that there are
specific receptors for the hormone in the kidney.
Calcitonin in vitro directly activates adenylate cyclase
and produces a rise in tissue concentration of 3',5'-
AMP in bone as well as in kidney [92—94]. The relative
potencies of various calcitonin analogues suggest also
that activation of adenylate cyclase is physiologically
involved in calcitonin action. Bioassay studies with
in vivo assays show that salmon calcitonin is the most
potent hormonal analogue. The order of potency is
as follows: salmon calcitonin > porcine calcitonin>
ovine calcitonin> bovine calcitonin > human calcito-
nm. This same order of potency is represented in the
effectiveness of these several analogues in activating
adenylate cyclase or increasing concentrations of
cyclic 3',5'-AMP in vitro [93]; concentrations of
salmon calcitonin as low as 1 ng/ml are effective.
The effects of calcitonin on adenylate cyclase are
specific for this hormone and distinct from effects of
parathyroid hormone on adenylate cyclase in bone or
kidney. Mixtures of parathyroid hormone and salmon
calcitonin at wide ranges of concentration consistently
produce additive effects in activating adenylate cyclase
and in increasing tissue concentrations of cyclic
3',5'-AMP [93]. The additive effects of parathyroid
hormone and calcitonin, even at maximal concentra-
tions of each hormone, are considered to be evidence
that receptors for the two hormones are distinct. This
is borne out also by differences in distribution of
parathyroid hormone and calcitonin-sensitive adeny-
late cyclases in the nephron [21, 94]. Thus, it is reason-
able to assume that receptors for the hormones are
discrete and that different cell types are involved in the
response to each hormone.
Calcitonin receptors. The overall conclusions just
set forth are borne out by experiments determining
the direct interaction of calcitonin with receptors in
kidney or bone. Radioiodinated calcitonin binds
specifically to receptors in plasma membranes from
the kidney or skeletal tissue [21, 94, 95]. Salmon
calcitonin shows the highest affinity for these receptors
with a dissociation constant in the range of 100 pM.
A series of calcitonin analogues produced a series
of parallel dose-response curves [21] with the sever-
al calcitonin analogues inhibiting binding of labelled
calcitonin (salmon). The apparent affinities of the
several calcitonin analogues (determined as compe-
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titive inhibitors of binding of 1251-labeled calcitonin)
paralleled biological effectiveness in vivo [21]. Thus, it
is apparent that biological effectiveness in vivo as well
as in vitro (determining adenylate cyclase activation or
cyclic AMP concentration) [93] parallels the affinity
of calcitonin analogues for specific receptors in kidney
and bone.
Interaction of other hormones with adenylate cyclase
in the kidney. The kidney contains receptors for
catecholamines and glucagon, in addition to those
already described herein for parathyroid hormone,
calcitonin and vasopressin. The effect of epinephrine
on renal adenylate cyclase is specifically blocked by
propanolol administration, whereas the effect of
parathyroid hormone is not [79, 96]. Studies with
bovine kidney indicate that the epinephrine sites are
located in a distribution distinct from those for para-
thyroid hormone [96]. The conclusion, then, is that,
although several hormones clearly stimulate adenylate
cyclase in the kidney, the loci of action of these hor-
mones are distributed in relatively distinct areas of the
nephron. The receptors for parathyroid hormone,
calcitonin and vasopressin, thus, are probably located
on three distinct cell types. Whether the epinephrine
and glucagon sites are located on two further distinct
cell types or whether they overlap with cell types
responding to the other hormones has not been estab-
lished by studies to date.
Only biologically active parathyroid hormone mole-
cules stimulate adenylate cyclase in the classically
recognized receptor tissues, kidney and bone. Admini-
stration of parathyroid hormone does not influence
adenylate cyclase significantly in skeletal muscle,
heart, brain, spleen, liver or other tissues known to
contain receptors for other hormones.
Role of cyclic 3',5'-AMP in ion transport. The evi-
dence already summarized herein suggests that it is
the rise in concentration of cyclic AMP within cells
of the specific receptor tissues that causes the ultimate
expression of the physiological response to parathyroid
hormone or calcitonin. A number of studies indicate
that in cells responding to hormones through the
intermediation of cyclic 3',5'-AMP, the cyclic nucleo-
tide causes activation of protein kinases. Cyclic
AMP-stimulated protein kinases have been detected
in renal cortex [97, 98]. The kinase is activated by
cyclic 3',5'-AMP with an apparent Km of 2 x 10 M.
A binding protein (cyclic 3',5'-AMP receptor protein)
shows the same affinity for cyclic 3',5'-AMP (2 x l0
M). In several tissues the binding protein and kinase
are separable in the presence of excess cyclic 3',5'-
AMP [99]. Activation of the kinase seems to involve
dissociation of the binding protein (which itself inhi-
bits the kinase enzyme) from the enzyme catalytic
unit (kinase). It is possible, then, that phosphorylation
of a particular substrate, catalyzed by protein kinases
intracellularly, is an intermediate step in the action of
parathyroid hormone on bone cells.
Sodium transport influenced by cyclic 3',5'-AMP.
Several systems have now been identified wherein
specific hormonal stimulation of adenylate cyclase
and generation of increased intracellular concentra-
tions of cyclic AMP cause an increase in sodium trans-
port. This mode of action was first recognized in the
toad bladder [32], which shows a prompt increase in
sodium and water transport in response to vasopressin
or cyclic 3',S'-AMP added in vitro. Epinephrine
administration causes a similar enhanced rate of
sodium transport in the frog skin in vitro [33], and in
avian erythrocytes [34, 35], -adrenergic catechola-
mines cause a striking increase in rate of sodium
transport. This effect too is mimicked by addition of
exogenous cyclic 3',5'-AMP. Cathecholamines also
seem to influence sodium transport in the kidney [20],
and Agus et al have shown that DCAMP can influence
proximal reabsorption of sodium in the renal tubule in
a manner similar to the effects of parathyroid hormone
[9]. Moreover, in several of these systems there are
suggestions that sodium transport is regulated through
a protein phosphorylation system which in turn may
be controlled by cyclic 3',5'-AMP. This control by
cyclic 3',5'-AMP may be mediated through the phos-
phoprotein kinase mechanism. It is possible that all of
the physiologically relevant effects of parathyroid
hormone and calcitonin on the kidney reflect this type
of cyclic AMP controlled sodium transport. Gener-
ation of cyclic 3',5'-AMP itself within regions of the
nephron presumably reflects interaction with specific
receptors for particular hormones in segregated loci.
Control of calcium through regulation of vitamin
D metabolism. Recent studies indicate that the action
of vitamin D is dependent upon conversion within the
body to 1 ,25-dihydroxycholecalciferol [100, 101].
Production of this metabolite depends upon two hy-
droxylation steps. The first hydroxylation, at the
25-position, takes place in the liver; the second, at
the 1-position, takes place in the kidney. This latter
hydroxylation at the 1-position appears to be under
the control of phosphate or parathyroid hormone or
both. There is also suggestive evidence that cyclic
3',5'-AMP is involved in activation of this renal
hydroxylation step [102]. This type of control mech-
anism might be analogous to the cyclic 3',5'-AMP-
mediated ACTH regulation of steroid hydroxylation
in the adrenal gland. Thus, regulation of 25-hydroxy-
vitamin D hydroxylase represents another mechanism
whereby cyclic AMP can control ion transport. The
1 ,25-dihydroxycholecalciferol formed in the kidney
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represents the active form of the vitamin which stimu-
lates intestinal absorption of calcium [100—102].
Cyclic nucleotides in extracellular fluids. The early
investigations of Sutherland and his collaborators
indicated that cyclic nucleotides indeed appear in the
extracellular fluids and that changes in hormonal status
can influence the concentration of cyclic nucleotides
in the body fluids. Some of their first experiments
showed that hypophysectomy reduced the urinary
excretion of cyclic 3',5'-guanine monophosphate
(GMP) and that this was restored towards normal by
administering thyroxine or mixtures of pituitary
hormones or both [103]. In the same set of studies,
however, they found that hypophysectomy was with-
out effect on urinary excretion of cyclic 3',5'-AMP,
even though certain pituitary hormones were known
to act through the intermediation of cyclic AMP in
specific receptor tissues. Subsequent work with many
systems in a number of laboratories made it clear
that part of the cyclic AMP generated intracellularly
in response to specific hormones in particular receptor
tissues is extruded (or possibly transported) into the
surrounding medium or body fluid.
For example, it is now recognized that cyclic AMP
content increases in the hepatic vein after stimulation
with glucagon [104], increases in the urine after injec-
tion of parathyroid hormone [72—74, 105] or vaso-
pressin [72, 105, 106], increases in adrenal vein plasma
after injection of ACTH (corticotropin) [107], and
increases in the general circulation after injection of
-adrenergic catecholamines in man [108].
Clearance of cyclic nucleotides from plasma. In
man the t4 for disappearance of cyclic AMP or cyclic
GMP from plasma is virtually identical, with the
mean t-- value in the range of 30 mm. Broadus et al
have carried out extensive studies on production rate
and clearance rates for cyclic AMP and cyclic GMP
in the plasma of man [109]. Both cyclic nucleotides
appear to distribute in a space exceeding the extra-
cellular fluid volume. Renal clearance of the cyclic
nucleotide into the urine accounts for only 20°/ of
the entire cyclic nucleotides cleared from the miscible
pool. In the dog, the kidney accounts for 30% of the
total clearance of cyclic 3',5'-AMP from plasma [110].
It is of interest that only two-thirds of this renal clear-
ance is accounted for by excretion. The remainder
appears to represent enzymatic destruction of nucleo-
tide within the kidney.
The major sites responsible for cyclic nucleotide
production under basal conditions have not been
clearly delineated. Although parathyroid hormone,
catecholamines, ACTH and glucagon in large doses
are capable of inducing an increase in plasma cyclic
AMP concentration, none of the corresponding recep-
tor tissues—liver, kidney or adrenal—seem to be the
major source for plasma cyclic AMP under resting
conditions [110, 111]. In the studies of Kaminsky et al
[74], it was possible to segregate cyclic 3',S'-AMP
appearing in urine according to nephrogenous or
systemic origin. Plasma cyclic AMP itself is cleared
by glomerular filtration into the urine; the renal
clearance of plasma cyclic AMP is equal to the
clearance of inulin. The amount cleared from the
plasma, however, represents only 50 to 60% of the
total cyclic 3',5'-AMP appearing in the urine. The
remaining 40 to 50% represents nephrogenously
generated cyclic 3',5'-AMP, and this nephrogenous
contribution is for the most part under the control of
parathyroid hormone. Induction of hypercalcemia
with consequent suppression of parathyroid hormone
secretion decreases the nephrogenous component by
about 80% Similarly, it is the nephrogenous compo-
nent that is increased following injection of parathy-
roid hormone. On the other hand, it is not possible to
suppress completely the nephrogenous contribution
by infusing calcium. This perhaps is not unexpected
in that catecholamines, calcitonin and vasopressin,
and possibly prostaglandins, are capable of influenc-
ing the nephrogenous component; and these factors
are not known to be suppressed or inhibited by hyper-
calcemia.
Effect of other hormones on cyclic nucleotide
excretion. Glucagon, vasopressin and catecholamines
also influence urinary excretion of cyclic 3',S'-AMP.
Like parathyroid hormone, vasopressin acts physio-
logically on renal tubular elements through activation
of adenylate cyclase and generation of cyclic 3',5'-
AMP. However, as already noted, vasopressin acts
predominantly in the distal tubular collecting duct
system of the nephron, a site distinct from the cortical
tubular region influenced by parathyroid hormone.
The distal tubular and collecting duct system seems
relatively less permeable to cyclic 3',S'-AMP in that
vasopressin at physiological concentrations does not
influence urinary cyclic AMP excretion significantly
[72]. Only with administration of large doses of vaso-
pressin is a significant (two-fold) increment in urinary
cyclic AMP excretion observed [72, 74, 106]. The small
increment in urinary cyclic AMP produced in response
to large doses of vasopressin presumably also is of
nephrogenous origin.
Glucagon also causes a marked increase in urinary
excretion of cyclic 3',5'-AMP [104]. However, this
effect of glucagon reflects the direct action of this
hormone on the liver. As a consequence, the concen-
tration of cyclic AMP in plasma increases markedly
and the cyclic nucleotide in plasma is then cleared by
glomerular filtration through the kidney. The effect
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of glucagon on urinary cyclic AMP is thus effected
through an entirely different mechanism than that of
parathyroid hormone. This can be recognized by
changes in cyclic 3',5'-AMP to inulin clearance ratios
[104].
Catecholamines also influence urinary excretion of
cyclic AMP, but the pattern is complex. /3-adrenergic
agonists cause an increase in plasma cyclic AMP, but
a decrease in overall clearance ratio of cyclic AMP to
inulin, as well as a reduction in apparent nephrogenous
contribution to urinary cyclic AMP [108]. Conversely,
a-adrenergic agonists seem to increase the nephro-
genous contribution to urinary cyclic AMP, even
though plasma concentrations do not change. The
/3-adrenergic agents do not influence the effect of
parathyroid hormone on urinary excretion of cyclic
AMP. It is possible that the apparent increase in
nephrogenous contribution to urinary cyclic AMP
produced by /3-adrenergic inhibition represents an
effect on renal vasculature with changes in distribution
of renal plasma flow.
Calcitonin and urinary excretion of cyclic nucleo-
tides. Although it is clear that there are specific
receptors for calcitonin in the kidney and that calci-
tonin in vitro causes an increase in adenylate cyclase
activity and cyclic AMP concentration in these cells,
there is little evidence that calcitonin influences directly
the urinary excretion of cyclic 3',5'-AMP. Calcitonin
administered to dogs or man [105] causes a modest
increase in cyclic AMP excretion, but this effect is
abolished by parathyroidectomy and probably repre-
sents increased secretion of parathyroid hormone.
Calcitonin causes little or no increase in cyclic 3',5'-
AMP excretion in parathyroidectomized rats or man
[72, 105].
Clinical correlations. The finding that parathyroid
hormone was an important influence on urinary
excretion of cyclic AMP in the rat [72] led to investiga-
tion of urinary cyclic AMP responses as an index of
clinical physiological or pathophysiological status.
(The dog does not seem to respond to parathyroid
hormone administration in terms of urinary excretion
of cyclic 3',5'-AMP [110].) In the rat, induction of
hypercalcemia and consequent inhibition of parathy-
roid hormone secretion caused an 80% reduction in
the rate of excretion of cyclic 3',5'-AMP into the urine.
It was postulated that this phenomenon could be
developed into a clinically useful test for hyperpara-
thyroidism [72]. Indeed, a number of studies have
shown that excretion of cyclic 3',5'-AMP into the
urine is higher than normal in hyperparathyroidism
[74, 105, 106, 112, 113]. Also, it has been observed
[74, 105] that infusion of calcium decreases urinary
cyclic 3',S'-AMP in normal human subjects. Of note,
however, is the fact that the degree of suppression of
excretion of cyclic nucleotide by calcium infusion is
much less in man than in rats. The differences might
be explained by disappearance rates for plasma cyclic
AMP. In the rat the tj- for cyclic AMP is very short,
two minutes or less [72], due to clearance by extra-
renal mechanisms including cyclic nucleotide-phospho-
diesterase action within the plasma compartment
itself. Thus, a much smaller fraction of plasma cyclic
AMP is excreted and the bulk of urinary cyclic AMP
in the rat represents nephrogenously generated cyclic
nucleotide, most of which is under control of para-
thyroid hormone. Inhibition of secretion of parathy-
roid hormone by hypercalcemia in the rat, then,
causes a marked reduction in the nephrogenous contri-
bution accounting for most of 3',S'-AMP excreted
by the rat. On the other hand, in human beings with
much slower rates of disappearance of plasma cyclic
3',5'-AMP, a major (50 to 60%) fraction of the excre-
ted cyclic 3',5'-AMP reflects that cleared from the
plasma; the latter component is virtually uninfluenced
by parathyroid hormone. Thus, the calcium infusion
test has not been as useful as predicted for segregating
normal subjects from those with hyperparathyroidism
using urinary cyclic AMP as an index. On the other
hand, the observations among a number of investiga-
tors show uniformly that excretion of cyclic 3',S'-
AMP is increased in hyperparathyroidism and returns
to the normal or low range following correction of
hyperparathyroidism by surgery [74, 105, 112, 113].
Hypoparathyroidism is characterized by diminished
rates of excretion of cyclic 3',S'-AMP (conveniently
expressed as ratio of cyclic AMP to creatinine).
Patients with idiopathic or surgical hypoparathyroid-
ism respond readily to i.v. administration of para-
thyroid hormone with a rapid and marked increase in
rate of excretion of cyclic 3',S'-AMP into the urine
[73].
Pseudohypoparathyroidism is a syndrome charac-
terized by a defect in the receptor tissues for para-
thyroid hormone and there is little or no response to
exogenous parathyroid hormone. The receptor tissues
as originally proposed by Albright et al [114] in this
disorder appear to be defective and incapable of res-
ponding to administration of parathyroid hormone.
The precise nature of this defect, however, is not
clear. In the one instance wherein it was possible to
test renal tissue taken from a patient with pseudohypo-
parathyroidism, the response to parathyroid hormone
administration appeared to be normal in terms of
adenylate cyclase activation by the hormone in vitro
[115]. Clearly, further studies of this nature are re-
quired before conclusions can be drawn, but it is
possible that the defect in pseudohypoparathyroidism
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does not represent lack of receptor or enzyme itself.
Guanine nucleotides and phospholipids are also
known to influence hormone adenylate cyclase inter-
actions, and it is possible that the defect lies at this
level or at some point as yet undiscovered. One report
[116] suggested that there may be a second form of
the disease wherein adenylate cyclase and cyclic
3',5'-AMP production are normal but the response
to the cyclic nucleotide is lacking. This result would be
expected if the cyclic nucleotide receptor protein
were defective.
There have been reports that the response to para-
thyroid hormone administration is abnormal in
certain clinical conditions other than pseudohypo-
parathyroidism. Defective phosphaturic responses
have been reported in basal cell nevus syndrome [117],
in Gardner's syndrome [118], and in hypomagnesemia
[119]. Reexamination of these conditions utilizing
urinary cyclic AMP as an index has shown that the
responses in basal cell nevus syndrome and Gardner's
syndrome are normal [120]. Hypomagnesemic rats
respond normally to exogenous parathyroid hormone
[121].
Effects of other physiological factors, hormones
and drugs. Exercise and upright posture increase
plasma and urinary cyclic AMP concentration. Excre-
tion of the nucleotide apparently increases also dur-
ing pregnancy and prior to the luteal phase of
the menstrual cycle. Hamet, Kuchel and Genest [122]
have found that labile hypertensive subjects differ
from normal subjects in response to upright posture or
fl-adrenergic stimulation. Upright posture or iso-
proterenol infusion causes a much greater and regular
increase in cyclic AMP excretion in the hypertensive
group. These observations may be related to the fact
that hypertensive subjects show an increased respon-
siveness of the renin-angiotensin system to the upright
posture. Taylor et al have observed a progressive
increase in urinary excretion of cyclic 3',5'-AMP in
pregnancy, and an increase also coinciding with
ovulation during the menstrual cycle [106]. These
findings suggest that gonadotropins may influence
urinary cyclic AMP. There is as yet no direct proof
for this, however. Exercise causes an increase in
plasma cyclic 3',5'-AMP [123] and this is reflected also
in an increased urinary excretion of cyclic 3',5'-AMP
after exercise [123, 124]. The excretion of cyclic AMP
into the urine increases in the manic phase of manic-
depressive psychosis [125]. This might reflect simply
an increase in physical activity. Children excrete
larger ratios of cyclic AMP/creatinine than is found in
adults [126].
Certain drugs influence the concentration of cyclic
3',5'-AMP in the extracellular fluids. The original
observation of Davoren and Sutherland indicated
that administration of probenecid prevented elabora-
tion of cyclic 3',5'-AMP from pigeon erythrocytes into
the surrounding medium [127]. A recent report [128]
shows that azetazolamide activates adenylate cyclase
in the renal cortex and produces an increase in tissue
concentration of cyclic 3',5'-AMP and urinary excre-
tion of the cyclic nucleotide similar to the effects of
parathyroid hormone. These studies are of consider-
able interest in terms of the mechanism of action of
parathyroid hormone which, like azetazolamide, can
produce proximal renal tubular acidosis [129].
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